Samples were tested for the presence of AIs (2-androstenol (5-androst-2-en-17-ol), 2-androstenone (5-androst-2-en-17-one), 3-androstenol (5-androst-3-en-17-ol), 3-androstenone (5-androst-3-en-17-one), 4-androstene-3,6,17 trione (6-oxo), aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), androsta-3,5-diene-7,17-dione (arimistane), exemestane, formestane, letrozole, and testolactone), and anti-estrogenic substance (bazedoxifene, clomiphene, cyclofenil, fulvestrant, ospemifene, raloxifene, tamoxifen, and toremifene) prohibited by WADA
On average, patients using both CGMs and GLP-1 drugs are exhibiting higher usage of both products
297(3): 1325 Simenhoff ML, Ginn HE, Teschan PE
Mindestkonzentration bei Topika
V glutathione l mt trong nhng cht lm trng da ph bin, rt c yu thch trong ngnh m phm